Lin S Cheng from Sunnyvale, CA, age 63

Lin Chengfeng

view source

Lin Cheng-feng (simplified Chinese: ; traditional Chinese: ; pinyin: Ln Zhngfng) born December 26, 1982, is a Taiwanese baseball player who ...

A Handbook of the Swatow Vernacular: [1886]

view source

Originally published in 1886. This volume from the Cornell University Library's print collections was scanned on an APT BookScan and converted to JPG 2000 format by Kirtas Technologies. All titles scanned cover to cover and pages may include marks notations and other marginalia present in the origin...

Author
Hsiung-cheng Lin

Binding
Paperback

Pages
306

Publisher
Cornell University Library

ISBN #
10

Building a Sacred Mountain: The Buddhist Architecture of China's Mount Wutai (Art History Publicatoin Initiative Books)

view source

By the tenth century CE, Mount Wutai had become a major pilgrimage site within the emerging culture of a distinctively Chinese Buddhism. Famous as the abode of the bodhisattva Mañjuśrī (known for his habit of riding around the mountain on a lion), the site in northeastern China’s Shanxi Province was...

Author
Wei-Cheng Lin

Binding
Hardcover

Pages
352

Publisher
University of Washington Press

ISBN #
0295993529

EAN Code
9780295993522

ISBN #
6

Neurogenic Tinnitus And Deafness-A Handbook of Acupuncture and Moxibustion Therapy (Chinese Edition)

view source

This book explicitly introduces acupuncture and moxibustion therapy of the disease mentioned in title. It is a valuable reference book in traditional Chinese medical science.

Author
luo cheng lin

Binding
Paperback

Pages
199

Publisher
China Medicine Science Press

ISBN #
7506750929

EAN Code
9787506750929

ISBN #
8

Yield Improvement | Failure Analysis | Engineering Data Analytics Solutions | Quality Control & Assurance

view source

Position:

Product Engineer at Finisar Corporation (NASDAQ: FNSR)

Location:

San Francisco Bay Area

Industry:

Telecommunications

Work:

Finisar Corporation (NASDAQ: FNSR) - United States
Product Engineer
Western Digital - Fremont, California 2006 - 2012
Senior Principle Engineer- Advance Integration / Failure Analysis
Western Digital - Fremont, California 2003 - 2006
Principal Engineer--Processs Integration
Read-Rite Corporation - Fremont, California 2001 - 2003
Senior Engineer-- Process Integration

Education:

University of Virginia
Master of Engineering (M.Eng.), Materials Science & Engineering James Madison University
Master of Science (M.S.), Computer Science University of Science and Technology of China
Bachelor of Science (B.S.), Materials Science and Engineering

Languages:

English
Chinese

Assistant Professor At The University Of Arizona

view source

Location:

Tucson, Arizona

Industry:

Accounting

Work:

The Ohio State University - The Max M. Fisher College of Business Sep 2007 - Jul 2012
Ph.D. Student in Accounting

Education:

The Ohio State University - The Max M. Fisher College of Business 2007 - 2012
Doctor of Philosophy (Ph.D.), Accounting The Ohio State University - The Max M. Fisher College of Business 2006 - 2007
Master of Accounting, Accounting York University 2002 - 2006
BAS, Accounting

Lin Cheng

view source

Location:

United States

Lin Cheng

view source

Location:

San Francisco Bay Area

Industry:

Computer Hardware

Lin Cheng

view source

Location:

United States

Lin Cheng

view source

Location:

San Francisco Bay Area

Industry:

Accounting

Sr. Software Engineer - Hewlett Packard

view source

Location:

San Francisco Bay Area

Industry:

Information Technology and Services

Strategic Advisor At Bigmachines

view source

Location:

San Francisco Bay Area

Industry:

Computer Software

Lin Cheng

view source

Specialties:

Anatomic Pathology & Clinical Pathology

Us Patents

Polymer Conjugates Of Opioid Antagonists
view source
US Patent:

7056500, Jun 6, 2006
Filed:

Oct 18, 2002
Appl. No.:

10/274296
Inventors:

Michael David Bentley - Huntsville AL, US
Michael James Roberts - Williamsburg VA, US
Xiaoming Shen - Madison AL, US
Lin Cheng - Huntsville AL, US
Assignee:

Nektar Therapeutics AL, Corporation - Huntsville AL
International Classification:

A81K 31/74
US Classification:

424 7818, 424 7826, 424 7827
Abstract:

The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.

Polymer Conjugates Of Opioid Antagonists
view source
US Patent:

7662365, Feb 16, 2010
Filed:

Jan 17, 2006
Appl. No.:

11/332964
Inventors:

Michael David Bentley - Huntsville AL, US
Michael James Roberts - Williamsburg VA, US
Xiaoming Shen - Madison AL, US
Lin Cheng - Huntsville AL, US
Assignee:

Nektar Therapeutics - San Carlos CA
International Classification:

A81K 31/74
US Classification:

424 7818, 424 7826, 424 7827
Abstract:

The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.

Chemically Modified Small Molecules
view source
US Patent:

7786133, Aug 31, 2010
Filed:

Dec 16, 2004
Appl. No.:

11/015196
Inventors:

Michael D. Bentley - Huntsville AL, US
Tacey X. Viegas - Madison AL, US
Richard R. Goodin - Fayerville TN, US
Lin Cheng - Huntsville AL, US
Xuan Zhao - Huntsville AL, US
Assignee:

Nektar Therapeutics - San Carlos CA
International Classification:

A61K 31/485
C07D 489/08
US Classification:

514282, 546 44
Abstract:

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer obtained from a monodisperse or bimodal water-soluble oligomer composition. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.

Chemically Modified Small Molecules
view source
US Patent:

8034825, Oct 11, 2011
Filed:

Jun 24, 2010
Appl. No.:

12/822935
Inventors:

Michael D. Bentley - Huntsville AL, US
Tacey X. Viegas - Madison AL, US
Richard R. Goodin - Fayerville TN, US
Lin Cheng - Huntsville AL, US
Xuan Zhao - Huntsville AL, US
Assignee:

Nektar Therapeutics - San Francisco CA
International Classification:

A61K 31/485
C07D 489/08
US Classification:

514282, 546 44
Abstract:

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer obtained from a monodisperse or bimodal water-soluble oligomer composition. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.

Stereoselective Reduction Of A Morphinone
view source
US Patent:

8183376, May 22, 2012
Filed:

Apr 19, 2007
Appl. No.:

12/297632
Inventors:

Lin Cheng - Huntsville AL, US
Michael D. Bentley - Huntsville AL, US
Assignee:

Nektar Therapeutics - San Francisco CA
International Classification:

C07D 489/02
US Classification:

546 45
Abstract:

A synthetic method is provided, wherein the method comprises stereoselectively reducing a ketone of a morphinone to form a reduced morphinone and optionally covalently attaching a water soluble polymer to the reduced morphinone.

Polymer Conjugates Of Opioid Antagonists
view source
US Patent:

8349307, Jan 8, 2013
Filed:

Oct 6, 2009
Appl. No.:

12/574335
Inventors:

Michael David Bentley - Huntsville AL, US
Michael James Roberts - Williamsburg VA, US
Xiaoming Shen - Madison AL, US
Lin Cheng - Huntsville AL, US
Assignee:

Nektar Therapeutics - San Francisco CA
International Classification:

A61K 31/74
US Classification:

424 7817
Abstract:

The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.

Stereoselective Reduction Of A Morphinone
view source
US Patent:

8563726, Oct 22, 2013
Filed:

Apr 13, 2012
Appl. No.:

13/447131
Inventors:

Lin Cheng - Huntsville AL, US
Michael D. Bentley - Huntsville AL, US
Assignee:

Nektar Therapeutics - San Francisco CA
International Classification:

C07D 489/02
US Classification:

546 45
Abstract:

A synthetic method is provided, wherein the method comprises stereoselectively reducing a ketone of a morphinone to form a reduced morphinone and optionally covalently attaching a water soluble polymer to the reduced morphinone.

Oligomer-Protease Inhibitor Conjugates
view source
US Patent:

8598364, Dec 3, 2013
Filed:

Mar 12, 2008
Appl. No.:

12/530363
Inventors:

Jennifer Riggs-Sauthier - Huntsville AL, US
Lin Cheng - Huntsville AL, US
Tacey X. Viegas - Madison AL, US
Xuyuan Gu - Madison AL, US
Franco J. Duarte - Huntsville AL, US
Wen Zhang - Madison AL, US
Assignee:

Nektar Therapeutics - San Francisco CA
International Classification:

C07D 239/02
C07D 401/00
C07D 217/00
C07D 405/00
C07D 213/00
C07D 277/30
C07D 493/00
C07D 307/02
C07F 9/28
C07F 9/06
US Classification:

548204, 544316, 544360, 546146, 5462821, 546332, 549222, 549464, 549475
Abstract:

The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.